Baltazar Mancilla-Gomez

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study.

Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study.

Journal: The Journal of clinical psychiatry

Published: August 06, 2025

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.

Journal: Science translational medicine

Published: April 02, 2025

Characterization of a Clinically and Biologically Defined Subgroup of Patients with Autism Spectrum Disorder and Identification of a Tailored Combination Treatment.

Characterization of a Clinically and Biologically Defined Subgroup of Patients with Autism Spectrum Disorder and Identification of a Tailored Combination Treatment.

Journal: Biomedicines

Published: March 22, 2024

Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder.

Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder.

Journal: Frontiers in psychiatry

Published: May 29, 2023

Understanding the patient and supporter journey in cocaine use disorder.

Understanding the patient and supporter journey in cocaine use disorder.

Journal: Frontiers in psychiatry

Published: May 29, 2023

MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose).

MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose).

Journal: Clinical and translational science

Published: May 26, 2023

Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments.

Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments.

Journal: Frontiers in psychiatry

Published: June 08, 2021

A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression.

A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression.

Journal: Frontiers in psychiatry

Published: December 12, 2020

Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers.

Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers.

Journal: NeuroImage

Published: September 07, 2020

Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.

Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.

Journal: Annals of neurology

Published: July 01, 2020

A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders.

A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: January 29, 2020

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.

Journal: Human molecular genetics

Published: June 20, 2018

Showing 1-12 of 44

Last Updated: 09/26/2026